Table 1.
Inhibition of cellular proliferation by WEHI-7326: a panel of cancer cell lines.
| Cell line | Type of cancer | IC50 (nM)* |
|---|---|---|
| LoVo | Colon carcinoma | 42.2 ± 9.9 |
| SW480 | Colon carcinoma | 39.5 ± 4.1 |
| LIM1899 | Colon carcinoma | 31.3 ± 2.6 |
| LIM 2537 | Colon carcinoma | 58.9 ± 7.5 |
| MDA-MB-231 | Breast carcinoma | 24.4 ± 3.1 |
| PC3 | Prostate carcinoma | 48.9 ± 11.1 |
| H1437 | Non-small cell lung carcinoma | 29.7 ± 10.8 |
| U87MGΔ2–7 | Glioblastoma expressing activated EGFR | 6.1 ± 1.6 |
| CEM | Leukemia, acute lymphoblastic | 3.99 ± 0.04 |
| CEM dEpoB30 | Leukemia (taxane resistant, β-tubulin mutation) | 1.67 ± 0.04 |
| CEM dEpoB300 | Leukemia (taxane resistant, β-tubulin mutation) | 6.51 ± 0.08 |
*72 h viability assay using CellTiterGlo or Alamar Blue (leukemia cell lines) reagent. IC50 values are the mean of 3 independent experiments run in duplicates shown with SEM.